Breaking News Instant updates and real-time market news.

FB

Facebook

$179.37

-8.4 (-4.47%)

, AFL

Aflac

$84.94

-6.75 (-7.36%)

16:19
01/12/18
01/12
16:19
01/12/18
16:19

On The Fly: Top stock stories for Friday

Stocks opened mixed with the Dow and S&P scoring new all-time highs and the Nasdaq struggling under the weight of Facebook (FB), whose CEO made some comments about the company's news feed that could be read as potentially liable to hurt the social media giant's revenue growth. The Nasdaq moved off its opening lows and caught up with the winning pace set by the other major averages. By the end of the session, all three major indexes were at all-time highs. ECONOMIC EVENTS: In the U.S., the consumer price index came in firmer for December, with the "core" rise of 0.3% topping the consensus forecast for a 0.2% monthly gain and the "headline" CPI in-line with expectations with a 0.1% monthly advance. December retail sales increased 0.4% for both the broader control group and the group excluding autos and gas, which was roughly in-line with expectations. Business inventories grew 0.4% in November, as expected. In energy news, Baker Hughes reported that the U.S. rig count is up 15 from last week to 939 rigs. COMPANY NEWS: Shares of JPMorgan (JPM) advanced 1.7% after the bank reported better than expected adjusted earnings and managed revenue in the fourth quarter. CEO Jamie Dimon said the enactment of tax reform is a "significant positive outcome for the country" and as a result of the tax plan the bank will be "increasing and accelerating" some of its investments in "employees, customers and communities" it serves. Well Fargo (WFC) also reported better than expected earnings but its revenue fell a bit short to the consensus forecast. Its shares were 0.7% lower after the report... Facebook shares slipped 4.5% after CEO Mark Zuckerberg posted an announcement to his Facebook profile which explained that he is directing his product teams to change the way that they build Facebook to focus more on "meaningful social interactions" rather than relevant content... Meanwhile, Lowe's (LOW) shares jumped 5.3% after Bloomberg reported that D.E. Shaw plans to build an activist stake in the company and intends to agitate for changes at the retailer... In addition, Aflac (AFL) shares fell 7.4% after The Intercept reported that nine former employees of the company claim that there is fraud and abuse across almost every aspect of the company. The article that revealed the allegations also cited three lawsuits that were previously unreported, and indicated the company's management and board knew about the claims and did not disclose any information to shareholders beyond vague statements about lawsuits. The insurer released a statement in response saying that such allegations are "false" and that the company intends to aggressively fight such allegations, beginning with the filing for their dismissal... Late in the day, Viacom (VIA, VIAB) jumped more than 9% after a report came out that Shari Redstone, president of National Amusements, which controls both CBS (CBS) and Viacom, concluded that a bigger footprint is necessary and is pushing to re-merge the two companies. MAJOR MOVERS: Among the notable gainers was Astronics (ATRO), which rose 15.6% after the company guided for fiscal 2018 revenue above consensus estimates. Also higher was Kohl's (KSS), which gained 4.5% after the stock was upgraded to Sector Perform at RBC Capital and to Overweight at JPMorgan. Among the noteworthy losers was Concert Pharmaceuticals (CNCE), which dropped 27.2% after the USPTO denied the company's request for a Post Grant Review on Incyte's (INCY) '335 patent for Jakafi. Also lower was GameStop (GME), which slid 11% after the game retailer reported on its holiday sales and said it now sees FY17 EPS near the middle of its prior guidance range. INDEXES: The Dow rose 228.46, or 0.89%, to 25,803.19, the Nasdaq gained 49.28, or 0.68%, to 7,261.06, and the S&P 500 advanced 17.69, or 0.64%, to 2,785.96.

FB

Facebook

$179.37

-8.4 (-4.47%)

AFL

Aflac

$84.94

-6.75 (-7.36%)

JPM

JPMorgan

$112.67

1.83 (1.65%)

WFC

Wells Fargo

$62.55

-0.46 (-0.73%)

LOW

Lowe's

$100.86

5.12 (5.35%)

ATRO

Astronics

$47.35

6.38 (15.57%)

KSS

Kohl's

$63.87

2.75 (4.50%)

CNCE

Concert Pharmaceuticals

$20.15

-7.531 (-27.21%)

INCY

Incyte

$94.07

1.01 (1.09%)

GME

GameStop

$17.76

-2.2 (-11.02%)

VIA

Viacom

$39.10

3.45 (9.68%)

VIAB

Viacom

$33.76

2.95 (9.57%)

CBS

CBS

$58.83

1.05 (1.82%)

  • 12

    Jan

  • 12

    Jan

  • 12

    Jan

  • 18

    Jan

  • 18

    Jan

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 08

    Feb

  • 08

    Feb

  • 15

    Feb

  • 27

    Feb

  • 01

    Mar

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

FB Facebook
$179.37

-8.4 (-4.47%)

01/12/18
KEYB
01/12/18
NO CHANGE
KEYB
Facebook selloff a buying opportunity, says KeyBanc
KeyBanc analyst Andy Hargreaves recommended buying Facebook on the selloff, saying the company remains inexpensive relative to its strong growth prospects. Hargreaves maintained an Overweight rating and $220 price target on Facebook shares.
01/12/18
01/12/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Facebook (FB) downgraded to Hold from Buy at Stifel with analyst Scott Devitt arguing there is currently "too much uncertainty" relating to the economic impact of the company's pending News Feed changes communicated in a post last night by CEO Mark Zuckerberg. 2. Snap (SNAP) downgraded to Underperform from Market Perform at Raymond James with analyst Aaron Kessler saying Snap is largely a Chat/Message app and not a camera company as it refers to itself. 3. Etsy (ETSY) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Brian Nowak citing valuation as being too expensive compared to its peers and the stock's historical average. 4. Comcast (CMCSA) downgraded to Buy from Action List Buy at TD Securities with analyst Vince Valentin citing recent shares strength and to make room of new Action List addition Shaw Communications (SJR), where he now sees better upside potential. 5. Electronic Arts (EA) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Brian Nowak citing disappointing "Star Wars: Battlefront 2" third party data. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/12/18
MSCO
01/12/18
NO CHANGE
Target $215
MSCO
Overweight
Morgan Stanley says Facebook still has multiple revenue levers amid uncertainty
Morgan Stanley analyst Brian Nowak noted that Facebook has announced plans to change its News Feed algorithm, which will essentially result in lower time spent on the platform. However, it is difficult to gauge the net impact of these changes and it is also unknown when these changes started, as prior commentary suggests they may have already been impacting results, Nowak tells investors. While the incremental near-term uncertainty will make Facebook "a show-me story" over the next few quarters, Nowak sees the company having multiple levers of ad revenue growth and he keeps an Overweight rating and $215 price target on the shares.
01/12/18
OPCO
01/12/18
NO CHANGE
OPCO
Facebook weakness a buying opportunity, says Oppenheimer
Oppenheimer analyst Jason Helfstein believes the recent weakness in Facebook, caused by Facebook CEO Mark Zuckerberg saying it would change the newsfeed algorithm to prioritize Social content above Publisher content, is a buying opportunity, as it shows how important the Facebook platform has become for users. Helfstein also noted that this change would also give Facebook a way to remove some of the "fake news" content that has become problematic. The analyst maintained an Outperform rating on Facebook shares. In late morning trading, Facebook shares are down 4.14% to $179.97.
AFL Aflac
$84.94

-6.75 (-7.36%)

01/12/18
EVER
01/12/18
NO CHANGE
Target $87
EVER
In Line
Aflac selloff on Intercept article an overreaction, says Evercore ISI
The Intercept's article today on Aflac is "filled with hyperbole, which reduces the credibility of the claims being brought," Evercore ISI analyst Thomas Gallagher tells investors in a research note. The analyst admits, however, that it is unclear to know whether the fraud allegations by former employees have any merit. Gallagher views the 8% selloff today in shares of Aflac as an overreaction. The stock is now pricing in a "reasonably high probability that there are systemic issues here," the analyst contends. He has an In Line rating on Aflac with an $87 price target. The stock in afternoon trading is down 8%, or $7.58, to $84.11.
09/26/17
09/26/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. JPMorgan (JPM) and PNC Financial (PNC) were downgraded to Hold from Buy at Deutsche Bank. 2. Aflac (AFL) downgraded to Sell from Neutral at Citi with analyst Suneet Kamath saying the company is at an inflection point as Aflac Japan is too large to show meaningful growth and Aflac U.S. is "too small to move the growth needle." 3. Cardtronics (CATM) downgraded to Market Perform from Outperform at William Blair with analyst Robert Napoli citing the changes in the Australian market. 4. Cheesecake Factory (CAKE), Shake Shack (SHAK), and Habit Restaurants (HABT) were downgraded to Neutral from Outperform at Wedbush. 5. Genocea (GNCA) downgraded to Hold from Buy at Stifel with analyst Stephen Willey saying his visibility and confidence "remains admittedly low" after the company shelved GEN-003 and said it will shift focus on immuno-oncology and the development of neoantigen cancer vaccines. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/09/18
WELS
01/09/18
NO CHANGE
Target $90
WELS
Market Perform
Aflac price target raised to $90 from $84 at Wells Fargo
Wells Fargo analyst Sean Dargan raised his price target for Aflac to $90 from $84 after adjusting his Q4 2017, 2018 and 2019 EPS estimates. The analyst reiterates a Market Perform rating on the shares.
10/18/17
GSCO
10/18/17
INITIATION
Target $88
GSCO
Neutral
Aflac initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Alex Scott started Aflac with a Neutral rating and $88 price target while initiating coverage of the life insurance industry with a Neutral coverage view.
JPM JPMorgan
$112.67

1.83 (1.65%)

01/12/18
ARGS
01/12/18
NO CHANGE
Target $125
ARGS
Buy
JPMorgan price target raised to $125 from $109 at Argus
Argus analyst Stephen Biggar increased his price target on JPMorgan to $125 from $109 after raising his 2018 EPS estimate to $8.72 from $7.66, mostly to account for the company's guidance toward a 19% effective tax rate in 2018. The 19% rate would be down from 32% paid in 2017, Biggar noted. He keeps a Buy rating on JPMorgan shares.
01/09/18
SOCG
01/09/18
DOWNGRADE
Target $120.5
SOCG
Hold
JPMorgan downgraded to Hold from Buy at Societe Generale
Societe Generale analyst Andrew Lim downgraded JPMorgan to Hold saying the stock is now fairly priced following the recent rally. The analyst raised his price target for the shares to $120.50 from $113.
12/21/17
BUCK
12/21/17
UPGRADE
Target $135
BUCK
Buy
JPMorgan upgraded to Buy on lower tax rate, share gains at Buckingham
As previously reported, Buckingham upgraded JPMorgan to Buy from Neutral and raised its price target to $135 from $100. Analyst James Mitchell raised estimates to reflect "sizable" earnings leverage from the lower tax rate and views increasing buybacks as a tailwind with potential regulatory reform accelerating capital returns. Mitchell views JPMorgan as having a best-in-class franchise with upside through market share gains on multiple fronts .
12/21/17
12/21/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Darden (DRI) upgraded to Buy from Hold at Argus with analyst John Staszak citing the company's "strong" second quarter report, contending that the company can transfer the initiatives to price aggressively, lower costs and increase customer traffic at Olive Garden to also improve results at its specialty brands. 2. Exxon Mobil (XOM) was upgraded to Focus List from Outperform and Royal Dutch Shell (RDS.A) was upgraded to Outperform at Scotia Howard Weil. 3. JPMorgan (JPM) and Wells Fargo (WFC) were upgraded to Buy from Neutral at Buckingham. 4. Community Bank System (CBU) upgraded to Hold from Sell at Sandler O'Neill. 5. Spirit Airlines (SAVE) upgraded to Buy from Hold at Deutsche Bank with analyst Michael Linenberg saying he believes Airline underperformers in 2017 could see the most upside in 2018 as their prospects improve. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
WFC Wells Fargo
$62.55

-0.46 (-0.73%)

01/10/18
ATLE
01/10/18
UPGRADE
ATLE
Neutral
Wells Fargo upgraded to Neutral from Underweight at Atlantic Equities
01/10/18
ATLE
01/10/18
UPGRADE
Target $64
ATLE
Neutral
Wells Fargo upgraded to Neutral at Atlantic Equities
As previously reported, Atlantic Equities analyst John Heagerty upgraded Wells Fargo (WFC) to Neutral from Underweight, as his analysis leads him to increase his FY18 EPS view by 11% on average for the banks he covers. He also sees positive secondary effects for the banks from higher U.S. GDP growth. Heagerty raised his price target on Wells Fargo shares to $64 from $55. The analyst also upgraded Morgan Stanley (MS) to Overweight this morning, citing the same analysis of the potential benefits from tax reform.
01/10/18
ATLE
01/10/18
UPGRADE
Target $61
ATLE
Overweight
Morgan Stanley upgraded on tax reform benefits at Atlantic Equities
As previously reported, Atlantic Equities analyst John Heagerty upgraded Morgan Stanley (MS) to Overweight from Neutral, as his analysis leads him to increase his FY18 EPS view by 11% on average for the banks he covers. He also sees positive secondary effects for the banks from higher U.S. GDP growth. Heagerty raised his price target on Morgan Stanley shares to $61 from $48. The analyst also upgraded Wells Fargo (WFC) to Neutral from Underweight this morning, citing the same analysis of the potential benefits from tax reform.
01/10/18
01/10/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wells Fargo (WFC) upgraded to Neutral from Underweight at Atlantic Equities by analyst John Heagerty, as his analysis leads him to increase his FY18 EPS view by 11% on average for the banks he covers. He also sees positive secondary effects for the banks from higher U.S. GDP growth. Heagerty raised his price target on Wells Fargo shares to $64 from $55. The analyst also upgraded Morgan Stanley (MS) to Overweight this morning, citing the same analysis of the potential benefits from tax reform. 2. Deere upgraded to Outperform from Sector Perform at RBC Capital by analyst Seth Weber, who said he is positive on the company's leadership position in North American farm machinery which is stabilizing and exposure to the earth moving equipment category. The analyst is also constructive on Deere's recent Wirten Group acquisition. 3. Target (TGT) upgraded to Positive from Neutral at Susquehanna. 4. State Street (STT) and BNY Mellon (BK) upgraded to Buy from Neutral at Citi, with analyst Keith Horowitz saying he thinks the trust banks are the best way to play the digital transformation to the cloud and finds the current valuation as attractive. 5. RBS (RBS) upgraded to Overweight from Equal Weight at Morgan Stanley. Analyst Alvaro Serrano also downgraded Barclays (BCS) and Lloyds Banking (LYG). This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
LOW Lowe's
$100.86

5.12 (5.35%)

01/05/18
LEHM
01/05/18
UPGRADE
Target $120
LEHM
Overweight
Lowe's upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Matthew McClintock upgraded Lowe's to Overweight and raised his price target for the shares to $120 from $85. The Trump tax reform positions the retail industry "exceptionally well" in 2018, McClintock tells investors in a research note. The analyst raised his sector rating to Positive from Negative. For Lowe's, he sees improved flexibility for the company to make necessary investments without negatively impacting earnings results.
01/05/18
01/05/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. CVS Health (CVS) upgraded to Overweight from Equal Weight at Morgan Stanley WITH analyst Ricky Goldwasser contending that its planned acquisition of Aetna (AET) creates a path for accelerating EBIT growth from synergies and new Aetna membership. 2. Eli Lilly (LLY) upgraded to Buy from Hold at Argus with analyst David Toung citing possible "blockbuster" launches of baricitinib and galcanezumab as well as a regulatory update on galcanezumab as potential 2018 catalysts. 3. Lowe's (LOW) was upgraded to Overweight from Equal Weight and Target (TGT) was upgraded to Equal Weight from Underweight at Barclays. 4. Foot Locker (FL) upgraded to Buy from Neutral at Buckingham with analyst Scott Krasik saying he believes key product assortments are improving and expects an inflection in comparables by the second quarter. 5. Jack in the Box (JACK) upgraded to Neutral from Sell at Goldman Sachs with analyst Karen Holthouse saying the company is a "strong beneficiary" of tax reform. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/05/18
LEHM
01/05/18
UPGRADE
Target $70
LEHM
Equal Weight
Target upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Matthew McClintock upgraded Target (TGT) to Equal Weight and raised his price target for the shares to $70 from $45. The Trump tax reform positions the retail industry "exceptionally well" in 2018, McClintock tells investors in a research note. The analyst raised his sector rating to Positive from Negative. For Target, he sees improved flexibility for the company to make necessary investments without negatively impacting earnings results. The analyst this morning also upgraded Lowe's (LOW) to Overweight.
01/05/18
ZELM
01/05/18
DOWNGRADE
ZELM
Hold
Lowe's downgraded to Hold from Buy at Zelman
ATRO Astronics
$47.35

6.38 (15.57%)

01/12/18
ADAM
01/12/18
NO CHANGE
Target $48
ADAM
Buy
Astronics revenue inflection not reflected yet in stock, says Canaccord
Canaccord analyst Ken Herbert noted Astronics announced an increase in 2018 revenue guidance with an increase in both its Aerospace and Test businesses. The analyst believes both should be a positive and he said estimates will move higher to reflect the likely tax benefits and will provide an additional tailwind. He does not believe the revenue inflection point has been fully reflected in the stock yet. Herbert reiterated his Buy rating and raised his price target to $48 from $46 on Astronics shares.
10/09/17
RBCM
10/09/17
NO CHANGE
Target $209
RBCM
Outperform
Defense and Aerospace sector poised for strong Q3, says RBC Capital
RBC Capital analyst Matthew McConnell previewed the Q3 earnings season for the defense and commercial aviation industries, raising price targets across the sectors. In defense, McConnell likes the companies with focus on international markets, where demand has not yet been reflected in orders or backlog. Among his favorites, McConnell raises the price target on Raytheon (RTN) to $209 from $193, General Dynamics (GD) to $241 from $220, Northrop Grumman (NOC) to $324 from $294, Lockheed Martin (LMT) to $327 from $289, and Triumph (TGI) to $38 from $33. He also states that there may be room for some consolidation in defense given that budget up-cycle is only 2 years old, profiling Astronics (ATRO), Barnes (B), Esterline (ESL), Heico (HEI), and Textron (TXT) as some of the potential targets. In commercial aviation, McConnell sees Boeing (BA) upside driven by continued strong air traffic growth, mature sales campaigns, and expectations for a strong wide-body replacement cycle starting in the early 2020s, raising his price target on Boeing to $269 from $235.
10/05/17
ADAM
10/05/17
NO CHANGE
Target $36
ADAM
Buy
Canaccord says time to revisit Astronics
Canaccord analyst Ken Herbert believes it is time to revisit Astronics as the shares have significantly underperformed the Aerospace & Defense sector and have not seen any real bounce amid the improved sentiment around the commercial aerospace cycle. He believes the current price represents a good risk/reward as growth in the aerospace sector has reached an inflection point. Herbert maintained his Buy rating and raised his price target to $36 from $34 on Astronics shares.
12/12/17
ADAM
12/12/17
NO CHANGE
Target $46
ADAM
Buy
Astronics price target raised to $46 from $40 at Canaccord
Canaccord analyst Ken Herbert adjusted Astronics estimates to reflect the recent closure of the Telefonix acquisition and believes the deal will add $10M in 2018 EBIT, or approximately 10c to earnings. The analyst raised Astronics' price target to $46 from $40 to reflect an improved 2018 outlook and reiterated his Buy rating on share.
KSS Kohl's
$63.87

2.75 (4.50%)

01/12/18
01/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dick's Sporting (DKS) upgraded to Buy from Hold at Deutsche Bank with analyst Mike Baker saying he believes industry trends are bottoming and notes that Dick's inventory levels are coming back into balance with demand, which should lessen the impact on gross margins. 2. eBay (EBAY) upgraded to Buy from Hold at SunTrust with analyst Youssef Squali citing an upbeat fourth quarter holiday sales boosting revenues and gross merchandise volume, prospects for higher growth in 2018 on platform improvements and marketing investment, lowers corporate tax rates, and lower repatriation tax rates that will bring "most of $8.7B" in overseas cash to be used in buybacks or M&A. 3. Costco (COST) upgraded to Buy from Accumulate at Gordon Haskett with analyst Chuck Grom citing his meeting with management. 4. Kohl's (KSS) was upgraded to Overweight from Neutral at JPMorgan and to Sector Perform from Underperform at RBC Capital. 5. Humana (HUM) and Anthem (ANTM) were upgraded to Buy from Hold at Jefferies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/12/18
BMOC
01/12/18
NO CHANGE
Target $60
BMOC
Market Perform
Kohl's price target raised to $60 from $43 at BMO Capital
BMO Capital analyst Wayne Hood raised his price target on Kohl's to $60 after the company's better than expected comps for November-December. Hood also noted the presentation from CEO Kevin Mansell at the ICR Conference that highlighted improving traffic and operations trends within the company's "Greatness Agenda" initiative launched in 2014 that was based on the pillars of "Easy Experience, Amazing Products, Personalized Connections, and Incredible Savings". The analyst keeps his Market Perform rating on Kohl's.
01/12/18
RBCM
01/12/18
UPGRADE
Target $60
RBCM
Sector Perform
Kohl's upgraded to Sector Perform at RBC Capital on improving comps
As reported earlier, RBC Capital analyst Brian Tunick upgraded Kohl's to Sector Perform from Underperform and raised his price target to $60 from $39. Tunick cites sequentially improving comps in 2017 that led to 7% SSS increase in the holiday period - "one of the strongest comps in retail" - along with the management's focus on store fleet optimization, cost management, and balance sheet control.
01/12/18
RBCM
01/12/18
UPGRADE
RBCM
Sector Perform
Kohl's upgraded to Sector Perform from Underperform at RBC Capital
CNCE Concert Pharmaceuticals
$20.15

-7.531 (-27.21%)

01/12/18
MZHO
01/12/18
DOWNGRADE
MZHO
Neutral
Concert Pharmaceuticals downgraded to Neutral from Buy at Mizuho
12/19/17
UBSW
12/19/17
NO CHANGE
Target $34
UBSW
Buy
Concert Pharmaceuticals price target raised to $34 from $22 at UBS
UBS analyst Jeffrey Hung raised his price target on Concert Pharmaceuticals to $34 from $22 to reflect higher than expected demand for novel alopecia treatments. He continues to see a substantial opportunity for its alopecia treatment and increased his launch assumptions. The analyst also pointed to the company's clinical candidates that demonstrate the strategic value of the platform and pipeline optionality. Hung reiterated his Buy rating on Concert Pharmaceuticals shares.
01/12/18
01/12/18
DOWNGRADE
Target $23

Neutral
Concert Pharmaceuticals downgraded on valuation, litigation overhang at Mizuho
As previously reported, Mizuho analyst Difei Yang downgraded Concert Pharmaceuticals (CNCE) to Neutral from Buy, calling the stock fairly valued at current levels. Additionally, while Yang does not believe the Patent Trial and Appeal Board decision to deny a Post Grant Review in the company's ongoing dispute with Incyte (INCY) has any implications for the ultimate outcome of Concert's trial, the decision does leave a litigation overhang on the stock. Also, two phase 3 trial readouts for AVP-786 were pushed out to 2019, leaving Concert with one less potential catalyst in 2018, said Yang, who keeps a $23 price target on the stock.
01/12/18
STFL
01/12/18
NO CHANGE
Target $27
STFL
Buy
Concert pullback on PTAB decision a buying opportunity, says Stifel
Stifel analyst Adam Walsh called the news that the USPTO denied Concert Pharmaceuticals' Post Grant Review petition on Incyte's (INCY) '335 patent for Jakafi a "setback," but "certainly not the end" for Concert's deuterated ruxolitinib for alopecia areata. The PTAB decision does not prohibit Concert from challenging the '335 patent's validity at a later time in court, noted Walsh, who also points out the Phase 2a trial in alopecia areata will continue as planned. The analyst, who sees today's pullback as a buying opportunity, keeps a Buy rating on Concert shares but lowered his price target on the stock to $27 from $30.
INCY Incyte
$94.07

1.01 (1.09%)

01/08/18
DBAB
01/08/18
NO CHANGE
Target $110
DBAB
Buy
Celgene deal 'incremental negative' for Incyte, says Deutsche Bank
Deutsche Bank analyst Navin Jacob calls Celgene's (CELG) acquisition of Impact Biomedicines "one step" in the right direction. The analyst estimates Impact's Jak2 inhibitor fedratinib can achieve 20% of peak Jakafi sales in myelofibrosis and polycythemia vera, which translates to $1B. The asset fits Celgene's business and the $2.4B that the company is paying over the next two years "doesn't appear egregious for a commercial ready asset," Jacob tells investors in a research note. The analyst also views Celgene's acquisition as an "incremental negative" for Incyte (INCY). Given direct overlap, any future potential acquisition of Incyte by Celgene has been removed, Jacob contends. He keeps a Hold rating on Celgene with a $110 price target.
01/08/18
STFL
01/08/18
NO CHANGE
STFL
Buy
NewLink Genetics timelines mostly in-line with prior guidance, says Stifel
Stifel analyst Stephen Willey noted that NewLink Genetics (NLNK) now expects to complete the majority of enrollment in the Indigo301 melanoma trial by year-end, versus its previous expectation to complete enrollment in 2018, which he said is likely due to additional time required for dose optimization of the novel indoximod salt formulation. The remainder of the 2018 calendar the company laid out is full of mostly expected catalysts and in-line with prior guidance, said Willey, who still expects NewLink to remain levered to Incyte's (INCY) date from the Phase 3 ECHO-301 trial. Willey keeps a Buy rating on NewLink shares.
GME GameStop
$17.76

-2.2 (-11.02%)

12/07/17
BARD
12/07/17
NO CHANGE
BARD
Data so far suggesting healthy holiday game sales, says Baird
Baird analyst Colin Sebastian noted that French game maker Ubisoft (UBSFY) raised its revenue and margin guidance for the December quarter, which he views as a slight positive for video game industry sales momentum this holiday season. Data also point to solid sales for both Sony's (SNE) PS4 and Nintendo's (NTDOY) Switch, which are a driver of software as well as a key catalyst for Gamestop (GME), Sebastian added. Other publicly traded companies in the video game space include Activision Blizzard (ATVI), Electronic Arts (EA), Take-Two (TTWO) and Microsoft (MSFT).
01/10/18
BARD
01/10/18
NO CHANGE
Target $23
BARD
Outperform
GameStop holiday results expected to be inline, says Baird
Baird analyst Colin Sebastian said he expects GameStop to report inline holiday sales, seeing strength in top-selling software and hardware products that should offset a few weak performers. He noted his channel checks do not include the sale of collectibles, which is becoming a larger part of GameStop's business. Sebastian reiterated his Outperform rating and $23 price target but said he would be more constructive on GameStop shares below $20.
11/30/17
LOOP
11/30/17
NO CHANGE
Target $28
LOOP
Buy
GameStop rollout of Pokemon Centers makes "infinite sense", says Loop Capital
Loop Capital analyst Anthony Chukumba says GameStop decision to roll out Pokemon Centers at its GameStop and ThinkGeek stores adds to the company's larger collectibles initiative and "makes infinite sense" due to the popularity of the franchise. Chukumba keeps his Buy rating and $28 price target on GameStop, saying collectibles are a natural product extension for its business.
01/12/18
LOOP
01/12/18
NO CHANGE
Target $26
LOOP
Buy
GameStop price target lowered to $26 from $28 at Loop Capital
Loop Capital analyst Anthony Chukumba said he saw several encouraging signs in GameStop's report of better than expected 2017 holiday sales. He keeps a Buy rating on the stock, but trimmed his price target on GameStop shares to $26 from $28, noting that the company also said it now sees FY17 EPS near the middle of its prior guidance range.
VIA Viacom
$39.10

3.45 (9.68%)

01/02/18
BRRR
01/02/18
DOWNGRADE
BRRR
Market Perform
Viacom downgraded to Market Perform after rally at Barrington
As previously reported, Barrington analyst James Goss downgraded Viacom to Market Perform from Outperform, noting that a recent rally in the stock has priced in some of the upside he expected from the company's turnaround efforts and that recovery, particularly at the Paramount, will remain "largely in the future."
12/27/17
LOOP
12/27/17
NO CHANGE
Target $27
LOOP
Hold
Loop trims Viacom price target to $27 on 'Downsizing' disappointment
Loop Capital analyst David Miller lowered his Q1 estimates for Viacom after "Downsizing" came in a far third at the domestic box office in its holiday weekend opening against "Last Jedi" and "Jumanji," noting this is "the latest in a long line of Studio misfires this year." He trimmed his price target on Viacom shares to $27 from $28 and maintains a Hold rating on the stock.
11/20/17
11/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Verizon (VZ) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jennifer Fritzsche saying after dropping 16% since mid-January, "much of the bad news is behind the stock" in terms of wireless service revenue declines. 2. 3D Systems (DDD) upgraded to Neutral from Underweight at Piper Jaffray with analyst Troy Jensen saying he sees limited downside from current share levels. 3. Viacom (VIAB, VIA) upgraded to Hold from Sell at Deutsche Bank with analyst Bryan Kraft saying he sees limited room for further multiple compression. 4. Maxwell (MXWL) upgraded to Buy from Neutral at Roth Capital with analyst Craig Irwin saying he sees consensus estimates as achievable for 2018, and merger synergies with NessCap should start making a more material contribution over the next few quarters. 5. National Beverage (FIZZ) upgraded to Positive from Neutral at Susquehanna with analyst Pablo Zuanic citing his increased conviction on the sales and bottom-line upside of the company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/20/17
DBAB
11/20/17
UPGRADE
Target $25
DBAB
Hold
Viacom upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Bryan Kraft upgraded Viacom to Hold saying he sees limited room for further multiple compression. The analyst believes reports of merger speculation in the media space should provide valuation support and he keeps a $25 price target for Viacom shares.
VIAB Viacom
$33.76

2.95 (9.57%)

01/04/18
WELS
01/04/18
NO CHANGE
Target $32
WELS
Market Perform
Viacom price target raised to $32 from $25 at Wells Fargo
Wells Fargo analyst Marci Ryvicker raised her price target for Viacom to $32 from $25 to incorporate tax reform. The analyst reiterates a Market Perform rating on the shares.
01/02/18
BRRR
01/02/18
DOWNGRADE
BRRR
Market Perform
Viacom downgraded to Market Perform from Outperform at Barrington
01/02/18
MACQ
01/02/18
DOWNGRADE
MACQ
Underperform
Viacom downgraded to Underperform from Neutral at Macquarie
CBS CBS
$58.83

1.05 (1.82%)

01/04/18
WELS
01/04/18
NO CHANGE
Target $70
WELS
Outperform
CBS price target lowered to $70 form $75 at Wells Fargo
Wells Fargo analyst Marci Ryvicker lowered her price target for CBS to $70 from $75 to incorporate tax reform. The analyst reiterates an Outperform rating on the shares.
01/04/18
WELS
01/04/18
NO CHANGE
WELS
Media sector upgraded to Over Weight from Market Weight at Wells Fargo
Wells Fargo analyst Marci Ryvicker upgraded the Media sector to Over Weight from Market Weight citing her positive views on shares of 21st Century Fox (FOXA), Disney (DIS), CBS (CBS) and AMC Networks (AMCX). Fox is the analyst's top near-term pick in the space, with Disney "a close second."
01/03/18
RBCM
01/03/18
NO CHANGE
Target $43
RBCM
Outperform
21st Century Fox price target raised to $43 from $34 at RBC Capital
RBC Capital analyst Steven Cahall raised his price target on 21st Century Fox (FOXA) to $43 and kept his Outperform rating in the wake of the asset sale to Disney (DIS). Cahall says the valuation on the SpinCo implies a 20% free cash flow yield relative to 7% at its peer CBS (CBS), and expects this discount to be corrected with an upside in the stock once the deal is fully priced in. The analyst also sees the immediate outlook for the company's revenue growth as "solid".
01/03/18
RBCM
01/03/18
NO CHANGE
Target $40
RBCM
Outperform
Lionsgate price target raised to $40 from $36 at RBC Capital
RBC Capital analyst Steven Cahall raised his price target on Lions Gate Entertainment (LGF.B) to $40, calling it his "Top smidcap" for 2018. Cahall says that the company is a "content pureplay", which makes it defensive to changes in the ecosystem, adding that it is also the "most likely acquisition target in the space." The analyst points to reduction in earnings volatility through Starz, which he believes has an upside to its current distribution of 25M subscriptions. While there have been a number of potential suitors that want to own content, Cahall believes CBS (CBS) is the most "logical" one.

TODAY'S FREE FLY STORIES

KORS

Michael Kors

$68.63

0.25 (0.37%)

, LULU

Lululemon

$106.18

-0.19 (-0.18%)

11:07
05/26/18
05/26
11:07
05/26/18
11:07
Periodicals
Dollar Tree looks interesting, Barron's says »

Next week, another 20…

KORS

Michael Kors

$68.63

0.25 (0.37%)

LULU

Lululemon

$106.18

-0.19 (-0.18%)

GME

GameStop

$12.64

-0.1 (-0.78%)

DLTR

Dollar Tree

$95.23

0.59 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 31

    May

  • 31

    May

  • 12

    Jun

  • 14

    Jun

  • 26

    Jun

KHC

Kraft Heinz

$57.78

0.72 (1.26%)

, QCOM

Qualcomm

$59.95

0.85 (1.44%)

10:58
05/26/18
05/26
10:58
05/26/18
10:58
Periodicals
Kraft Heinz, J&J among safe, 'solid' dividend stocks, Barron's says »

Kraft Heinz (KHC),…

KHC

Kraft Heinz

$57.78

0.72 (1.26%)

QCOM

Qualcomm

$59.95

0.85 (1.44%)

MRK

Merck

$59.08

-0.03 (-0.05%)

TGT

Target

$71.22

0.28 (0.39%)

OMC

Omnicom

$71.98

-0.1 (-0.14%)

CCL

Carnival

$64.27

0.12 (0.19%)

JNJ

Johnson & Johnson

$121.40

0.06 (0.05%)

MMM

3M

$198.98

-0.38 (-0.19%)

LLY

Eli Lilly

$82.75

0.05 (0.06%)

VLO

Valero

$118.81

-3.06 (-2.51%)

EMR

Emerson

$72.50

-0.77 (-1.05%)

WBA

Walgreens Boots Alliance

$63.52

0.09 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

  • 30

    May

  • 02

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 12

    Jun

  • 19

    Jun

  • 10

    Sep

  • 23

    Oct

MU

Micron

$61.33

-0.15 (-0.24%)

10:48
05/26/18
05/26
10:48
05/26/18
10:48
Periodicals
Micron can solve low valuation, Barron's says »

Micron's stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 20

    Jun

ATUS

Altice USA

$18.50

-0.05 (-0.27%)

10:40
05/26/18
05/26
10:40
05/26/18
10:40
Periodicals
Altice's spinoff could be winning bet, Barron's says »

On June 8, Altice will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

MU

Micron

$61.33

-0.15 (-0.24%)

, XLNX

Xilinx

$69.63

0.88 (1.28%)

10:35
05/26/18
05/26
10:35
05/26/18
10:35
Periodicals
AI revolution just getting started, Barron's says »

Artificial Intelligence…

MU

Micron

$61.33

-0.15 (-0.24%)

XLNX

Xilinx

$69.63

0.88 (1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 20

    Jun

ZTCOY

ZTE Corp.

$0.00

(0.00%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:08
05/26/18
05/26
08:08
05/26/18
08:08
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

ZTCOY

ZTE Corp.

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$21.82

-0.445 (-2.00%)

HMC

Honda

$32.04

-0.34 (-1.05%)

NSANY

Nissan

$0.00

(0.00%)

F

Ford

$11.51

-0.11 (-0.95%)

GM

General Motors

$38.30

-0.09 (-0.23%)

TM

Toyota

$129.97

-2.47 (-1.87%)

VLKAY

Volkswagen

$0.00

(0.00%)

BAC

Bank of America

$30.16

-0.03 (-0.10%)

C

Citi

$68.42

-0.86 (-1.24%)

GS

Goldman Sachs

$235.05

-1.1 (-0.47%)

JPM

JPMorgan

$110.62

-0.64 (-0.58%)

MS

Morgan Stanley

$53.02

-0.96 (-1.78%)

USB

U.S. Bancorp

$50.54

-0.14 (-0.28%)

WFC

Wells Fargo

$54.91

0.25 (0.46%)

TWTR

Twitter

$33.64

0.11 (0.33%)

AA

Alcoa

$47.92

-1.26 (-2.56%)

CENX

Century Aluminum

$16.27

-0.07 (-0.43%)

AOBC

American Outdoor Brands

$12.53

0.05 (0.40%)

RGR

Sturm, Ruger

$63.10

0.5 (0.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 30

    May

  • 01

    Jun

  • 06

    Jun

  • 20

    Jun

  • 22

    Jun

  • 13

    Jul

  • 27

    Jul

  • 10

    Sep

  • 12

    Oct

  • 14

    Jan

  • 15

    Apr

  • 15

    Jul

  • 15

    Oct

HCLP

Hi-Crush Partners

$13.20

-0.825 (-5.88%)

17:54
05/25/18
05/25
17:54
05/25/18
17:54
Hot Stocks
Hi-Crush Partners provides update on bulldozer incident in Whitehall facility »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$77.98

1.49 (1.95%)

17:37
05/25/18
05/25
17:37
05/25/18
17:37
Hot Stocks
Post Holdings reports fire in Michael Foods' plant in Pennsylvania »

Post Holdings reported a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

ABMD

Abiomed

$394.49

0.04 (0.01%)

, WYN

Wyndham

$107.98

-0.58 (-0.53%)

17:34
05/25/18
05/25
17:34
05/25/18
17:34
Hot Stocks
Abiomed to enter S&P 500 index on May 31 »

S&P MidCap 400…

ABMD

Abiomed

$394.49

0.04 (0.01%)

WYN

Wyndham

$107.98

-0.58 (-0.53%)

MSCC

Microsemi

$68.74

0.005 (0.01%)

PRAH

PRA Health

$81.19

0.33 (0.41%)

GME

GameStop

$12.64

-0.1 (-0.78%)

FRED

Fred's

$1.69

0.05 (3.05%)

PRSP

Symbol now PB

$0.00

(0.00%)

RRTS

Roadrunner

$2.19

0.04 (1.86%)

DXC

DXC Technology

$94.20

-5.42 (-5.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 05

    Jun

  • 12

    Jun

PRAH

PRA Health

$81.19

0.33 (0.41%)

, ABMD

Abiomed

$394.49

0.04 (0.01%)

17:24
05/25/18
05/25
17:24
05/25/18
17:24
Hot Stocks
Breaking Hot Stocks news story on PRA Health, Abiomed »

PRA Health to replace…

PRAH

PRA Health

$81.19

0.33 (0.41%)

ABMD

Abiomed

$394.49

0.04 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

  • 12

    Jun

WYN

Wyndham

$107.98

-0.58 (-0.53%)

, MSCC

Microsemi

$68.74

0.005 (0.01%)

17:23
05/25/18
05/25
17:23
05/25/18
17:23
Hot Stocks
Breaking Hot Stocks news story on Wyndham, Microsemi »

Wyndham to replace…

WYN

Wyndham

$107.98

-0.58 (-0.53%)

MSCC

Microsemi

$68.74

0.005 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$394.49

0.04 (0.01%)

, WYN

Wyndham

$107.98

-0.58 (-0.53%)

17:21
05/25/18
05/25
17:21
05/25/18
17:21
Hot Stocks
Breaking Hot Stocks news story on Abiomed, Wyndham »

ABIOMED to replace…

ABMD

Abiomed

$394.49

0.04 (0.01%)

WYN

Wyndham

$107.98

-0.58 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

  • 12

    Jun

PCG

PG&E

$44.67

0.84 (1.92%)

17:16
05/25/18
05/25
17:16
05/25/18
17:16
Periodicals
CA Forestry Dept rules PG&E equipment responsible for wildfires, Bloomberg says »

Report filed by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FARM

Farmer Bros.

$28.50

0.15 (0.53%)

17:09
05/25/18
05/25
17:09
05/25/18
17:09
Hot Stocks
Levin Capital Strategies reports 8.4% stake in Farmer Bros »

Levin Capital purchased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$8.90

-0.35 (-3.78%)

17:07
05/25/18
05/25
17:07
05/25/18
17:07
Syndicate
Breaking Syndicate news story on Noodles & Company »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$1.22

-0.125 (-9.29%)

17:06
05/25/18
05/25
17:06
05/25/18
17:06
Hot Stocks
Windstream completes one-for-five reverse stock split »

Windstream completed its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$8.90

-0.35 (-3.78%)

17:06
05/25/18
05/25
17:06
05/25/18
17:06
Syndicate
Breaking Syndicate news story on Noodles & Company »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPD

Enterprise Products

$27.87

-0.12 (-0.43%)

17:01
05/25/18
05/25
17:01
05/25/18
17:01
Hot Stocks
Enterprise Products conduts open season for West Texas Crude oil expansion »

Enterprise Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INO

Inovio

$4.89

0.06 (1.24%)

16:37
05/25/18
05/25
16:37
05/25/18
16:37
Syndicate
Breaking Syndicate news story on Inovio »

Inovio files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$10.14

0.13 (1.30%)

16:36
05/25/18
05/25
16:36
05/25/18
16:36
Hot Stocks
Rent-A-Center 16.8% shareholder Engaged Capital nominates Carol McFate to Board »

On May 25, 2018, Engaged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$0.59

0.0086 (1.48%)

16:34
05/25/18
05/25
16:34
05/25/18
16:34
Hot Stocks
Akers Biosciences receives delinquency notice from NASDAQ »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHCP

Ditech

$6.60

0.37 (5.94%)

16:31
05/25/18
05/25
16:31
05/25/18
16:31
Hot Stocks
Ditech discloses receipt of late filing notice from NYSE »

Ditech Holding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$28.15

-4.82 (-14.62%)

, FL

Foot Locker

$55.97

9.585 (20.67%)

16:30
05/25/18
05/25
16:30
05/25/18
16:30
General news
On The Fly: Top stock stories for Friday »

Stocks on Wall Street…

GPS

Gap

$28.15

-4.82 (-14.62%)

FL

Foot Locker

$55.97

9.585 (20.67%)

HLF

Herbalife Nutrition

$48.76

-5.09 (-9.45%)

IEP

Icahn Enterprises

$69.41

0.22 (0.32%)

FCAU

Fiat Chrysler

$21.82

-0.445 (-2.00%)

DGX

Quest Diagnostics

$105.89

5 (4.96%)

UNH

UnitedHealth

$244.96

2.23 (0.92%)

ROST

Ross Stores

$77.35

-5.6 (-6.75%)

ADSK

Autodesk

$132.80

-5.96 (-4.30%)

AAL

American Airlines

$44.89

1.34 (3.08%)

LUV

Southwest

$52.86

1.65 (3.22%)

DAL

Delta Air Lines

$55.89

1.48 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 30

    May

  • 30

    May

  • 12

    Jun

  • 13

    Jun

  • 14

    Jun

  • 26

    Jun

  • 29

    Jun

16:30
05/25/18
05/25
16:30
05/25/18
16:30
Options
Preliminary option volume of 16.4M today »

Preliminary option volume…

VTL

Vital Therapies

$5.65

-0.475 (-7.76%)

16:26
05/25/18
05/25
16:26
05/25/18
16:26
Syndicate
Breaking Syndicate news story on Vital Therapies »

Vital Therapies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.